Alnylam Pharmaceuticals, Inc. (NASDAQ:ALNY) Shares Purchased by Swiss National Bank

Swiss National Bank increased its stake in shares of Alnylam Pharmaceuticals, Inc. (NASDAQ:ALNY) by 23.4% in the 1st quarter, HoldingsChannel reports. The firm owned 432,624 shares of the biopharmaceutical company’s stock after purchasing an additional 82,000 shares during the period. Swiss National Bank’s holdings in Alnylam Pharmaceuticals were worth $47,091,000 as of its most recent SEC filing.

Several other large investors have also added to or reduced their stakes in the company. Utah Retirement Systems boosted its position in shares of Alnylam Pharmaceuticals by 0.5% during the 4th quarter. Utah Retirement Systems now owns 20,172 shares of the biopharmaceutical company’s stock worth $2,323,000 after acquiring an additional 100 shares in the last quarter. Piedmont Investment Advisors Inc. boosted its position in shares of Alnylam Pharmaceuticals by 1.7% during the 4th quarter. Piedmont Investment Advisors Inc. now owns 6,686 shares of the biopharmaceutical company’s stock worth $770,000 after acquiring an additional 113 shares in the last quarter. Stifel Financial Corp boosted its position in shares of Alnylam Pharmaceuticals by 2.9% during the 3rd quarter. Stifel Financial Corp now owns 4,084 shares of the biopharmaceutical company’s stock worth $328,000 after acquiring an additional 114 shares in the last quarter. Trexquant Investment LP boosted its position in shares of Alnylam Pharmaceuticals by 3.7% during the 4th quarter. Trexquant Investment LP now owns 5,949 shares of the biopharmaceutical company’s stock worth $685,000 after acquiring an additional 214 shares in the last quarter. Finally, Dai Ichi Life Insurance Company Ltd boosted its position in shares of Alnylam Pharmaceuticals by 2.9% during the 4th quarter. Dai Ichi Life Insurance Company Ltd now owns 7,536 shares of the biopharmaceutical company’s stock worth $868,000 after acquiring an additional 214 shares in the last quarter. 92.81% of the stock is owned by institutional investors and hedge funds.

Several research firms have recently issued reports on ALNY. Morgan Stanley upped their price objective on Alnylam Pharmaceuticals from $148.00 to $162.00 and gave the stock an “overweight” rating in a research report on Thursday, May 7th. BidaskClub cut Alnylam Pharmaceuticals from a “strong-buy” rating to a “buy” rating in a research report on Thursday, April 30th. Evercore ISI began coverage on Alnylam Pharmaceuticals in a research report on Friday, April 24th. They set a “buy” rating and a $160.00 price objective for the company. JPMorgan Chase & Co. downgraded Alnylam Pharmaceuticals from an “overweight” rating to a “neutral” rating and boosted their target price for the company from $133.00 to $137.00 in a report on Thursday, May 7th. They noted that the move was a valuation call. Finally, Berenberg Bank began coverage on Alnylam Pharmaceuticals in a report on Thursday, March 19th. They issued a “buy” rating and a $200.00 target price for the company. One equities research analyst has rated the stock with a sell rating, five have given a hold rating and sixteen have given a buy rating to the stock. The stock currently has an average rating of “Buy” and a consensus target price of $143.75.

In related news, EVP Laurie Keating sold 10,000 shares of Alnylam Pharmaceuticals stock in a transaction dated Monday, April 20th. The stock was sold at an average price of $139.00, for a total value of $1,390,000.00. Following the completion of the transaction, the executive vice president now directly owns 24,492 shares in the company, valued at $3,404,388. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which can be accessed through the SEC website. Also, COO Yvonne Greenstreet sold 7,811 shares of Alnylam Pharmaceuticals stock in a transaction dated Tuesday, May 5th. The stock was sold at an average price of $140.00, for a total value of $1,093,540.00. Following the completion of the transaction, the chief operating officer now owns 11,070 shares of the company’s stock, valued at $1,549,800. The disclosure for this sale can be found here. Insiders have sold 96,812 shares of company stock valued at $13,878,051 over the last 90 days. Insiders own 3.50% of the company’s stock.

Shares of Alnylam Pharmaceuticals stock opened at $140.52 on Friday. The business has a 50-day moving average of $131.05 and a 200-day moving average of $117.87. The company has a debt-to-equity ratio of 0.20, a quick ratio of 4.48 and a current ratio of 4.68. Alnylam Pharmaceuticals, Inc. has a 1-year low of $65.89 and a 1-year high of $151.84.

Alnylam Pharmaceuticals (NASDAQ:ALNY) last announced its earnings results on Wednesday, May 6th. The biopharmaceutical company reported ($1.62) earnings per share for the quarter, beating the consensus estimate of ($1.89) by $0.27. The company had revenue of $71.94 million during the quarter, compared to the consensus estimate of $90.45 million. Alnylam Pharmaceuticals had a negative return on equity of 57.63% and a negative net margin of 310.01%. The company’s revenue was up 173.6% on a year-over-year basis. During the same period last year, the firm earned ($1.42) earnings per share. As a group, analysts predict that Alnylam Pharmaceuticals, Inc. will post -6.2 EPS for the current fiscal year.

Alnylam Pharmaceuticals Company Profile

Alnylam Pharmaceuticals, Inc, a biopharmaceutical company, focuses on discovering, developing, and commercializing RNA interference (RNAi) therapeutics. The company's pipeline of investigational RNAi therapeutics focus on genetic medicines, cardio-metabolic diseases, hepatic infectious diseases, and central nervous system/ocular diseases.

See Also: Dogs of the Dow

Want to see what other hedge funds are holding ALNY? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Alnylam Pharmaceuticals, Inc. (NASDAQ:ALNY).

Institutional Ownership by Quarter for Alnylam Pharmaceuticals (NASDAQ:ALNY)

Receive News & Ratings for Alnylam Pharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Alnylam Pharmaceuticals and related companies with MarketBeat.com's FREE daily email newsletter.